These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 15886245)

  • 1. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes.
    Mari A; Sallas WM; He YL; Watson C; Ligueros-Saylan M; Dunning BE; Deacon CF; Holst JJ; Foley JE
    J Clin Endocrinol Metab; 2005 Aug; 90(8):4888-94. PubMed ID: 15886245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes.
    Azuma K; Rádiková Z; Mancino J; Toledo FG; Thomas E; Kangani C; Dalla Man C; Cobelli C; Holst JJ; Deacon CF; He Y; Ligueros-Saylan M; Serra D; Foley JE; Kelley DE
    J Clin Endocrinol Metab; 2008 Feb; 93(2):459-64. PubMed ID: 18042650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients.
    Balas B; Baig MR; Watson C; Dunning BE; Ligueros-Saylan M; Wang Y; He YL; Darland C; Holst JJ; Deacon CF; Cusi K; Mari A; Foley JE; DeFronzo RA
    J Clin Endocrinol Metab; 2007 Apr; 92(4):1249-55. PubMed ID: 17244786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year.
    Ahrén B; Pacini G; Foley JE; Schweizer A
    Diabetes Care; 2005 Aug; 28(8):1936-40. PubMed ID: 16043735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of DPP-4 with vildagliptin improved insulin secretion in response to oral as well as "isoglycemic" intravenous glucose without numerically changing the incretin effect in patients with type 2 diabetes.
    Vardarli I; Nauck MA; Köthe LD; Deacon CF; Holst JJ; Schweizer A; Foley JE
    J Clin Endocrinol Metab; 2011 Apr; 96(4):945-54. PubMed ID: 21239518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance.
    Rosenstock J; Foley JE; Rendell M; Landin-Olsson M; Holst JJ; Deacon CF; Rochotte E; Baron MA
    Diabetes Care; 2008 Jan; 31(1):30-5. PubMed ID: 17947341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes.
    Pratley RE; Salsali A
    Curr Med Res Opin; 2007 Apr; 23(4):919-31. PubMed ID: 17407649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Feedback suppression of meal-induced glucagon-like peptide-1 (GLP-1) secretion mediated through elevations in intact GLP-1 caused by dipeptidyl peptidase-4 inhibition: a randomized, prospective comparison of sitagliptin and vildagliptin treatment.
    Baranov O; Kahle M; Deacon CF; Holst JJ; Nauck MA
    Diabetes Obes Metab; 2016 Nov; 18(11):1100-1109. PubMed ID: 27300579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dipeptidyl peptidase 4 (DPP-4) is expressed in mouse and human islets and its activity is decreased in human islets from individuals with type 2 diabetes.
    Omar BA; Liehua L; Yamada Y; Seino Y; Marchetti P; Ahrén B
    Diabetologia; 2014 Sep; 57(9):1876-83. PubMed ID: 24939431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vildagliptin: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties.
    Ahrén B
    Expert Opin Investig Drugs; 2006 Apr; 15(4):431-42. PubMed ID: 16548792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hormonal and metabolic effects of morning or evening dosing of the dipeptidyl peptidase IV inhibitor vildagliptin in patients with type 2 diabetes.
    He YL; Valencia J; Zhang Y; Schwartz SL; Ligueros-Saylan M; Foley J; Dole WP
    Br J Clin Pharmacol; 2010 Jul; 70(1):34-42. PubMed ID: 20642545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of dipeptidyl peptidase IV inhibition on glycemic, gut hormone, triglyceride, energy expenditure, and energy intake responses to fat in healthy males.
    Heruc GA; Horowitz M; Deacon CF; Feinle-Bisset C; Rayner CK; Luscombe-Marsh N; Little TJ
    Am J Physiol Endocrinol Metab; 2014 Nov; 307(9):E830-7. PubMed ID: 25231186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response.
    Ristic S; Byiers S; Foley J; Holmes D
    Diabetes Obes Metab; 2005 Nov; 7(6):692-8. PubMed ID: 16219012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counterregulation during hypoglycemia in type 1 diabetes.
    Farngren J; Persson M; Schweizer A; Foley JE; Ahrén B
    J Clin Endocrinol Metab; 2012 Oct; 97(10):3799-806. PubMed ID: 22855332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes.
    Pratley RE; Jauffret-Kamel S; Galbreath E; Holmes D
    Horm Metab Res; 2006 Jun; 38(6):423-8. PubMed ID: 16823726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of long-term treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin on islet endocrine cells in non-obese type 2 diabetic Goto-Kakizaki rats.
    Inaba W; Mizukami H; Kamata K; Takahashi K; Tsuboi K; Yagihashi S
    Eur J Pharmacol; 2012 Sep; 691(1-3):297-306. PubMed ID: 22820107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The islet enhancer vildagliptin: mechanisms of improved glucose metabolism.
    Ahrén B; Foley JE
    Int J Clin Pract Suppl; 2008 Mar; (159):8-14. PubMed ID: 18269436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dipeptidyl peptidase-4 inhibition by vildagliptin and the effect on insulin secretion and action in response to meal ingestion in type 2 diabetes.
    Dalla Man C; Bock G; Giesler PD; Serra DB; Ligueros Saylan M; Foley JE; Camilleri M; Toffolo G; Cobelli C; Rizza RA; Vella A
    Diabetes Care; 2009 Jan; 32(1):14-8. PubMed ID: 18931099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database.
    Pratley RE; Schweizer A; Rosenstock J; Foley JE; Banerji MA; Pi-Sunyer FX; Mills D; Dejager S
    Diabetes Obes Metab; 2008 Sep; 10(10):931-8. PubMed ID: 18093207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes.
    Ahrén B; Schweizer A; Dejager S; Dunning BE; Nilsson PM; Persson M; Foley JE
    J Clin Endocrinol Metab; 2009 Apr; 94(4):1236-43. PubMed ID: 19174497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.